UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): September 13, 2025~~1934

Date of Report (date of earliest event reported): November 4, 2025

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware(State or other jurisdiction of incorporation)	001-34180(Commission File Number)	77-0513190(I.R.S. Employer Identification Number)
Delaware(State or other jurisdiction of incorporation or organization)	001-34180(Commission File Number)	77-0513190(I.R.S. Employer Identification Number)
2 Tower Place, Suite 2000South San Francisco, California 94080
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, $0.001 par value per share	LAB	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule ~~405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule~~ 12b-2 of the ~~Securities~~ Exchange Act ~~of 1934 (§240~~.~~12b-2 of this chapter).~~

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.~~05.~~02 ~~Costs~~- ~~Associated~~Results ~~with~~of ~~Exit~~Operations orand ~~Disposal~~Financial ~~Activities~~Condition

On ~~September~~November 134, 2025, Standard BioTools Inc. ~~(the~~issued ~~“Company”) commenced~~ a ~~restructuring~~press ~~plan,~~release ~~including~~which aincluded ~~reduction-in-force~~information ofwith ~~approximately~~respect ~~15%~~to ofcertain ~~its~~financial ~~total~~results ~~global~~for ~~workforce. The purpose of this restructuring plan, including~~ the ~~reduction-in-force,~~three ~~is to improve operational efficiency~~ and ~~reduce~~nine ~~operating~~months ~~costs~~ended ofSeptember ~~its continuing operations in line with the Company’s current revenue projections~~30, ~~while~~2025. ~~supporting~~The ~~the~~press ~~execution~~release ofis ~~the~~attached ~~Company’s~~hereto ~~long-term~~as ~~strategic~~Exhibit ~~plan~~99. 1.

The ~~Company~~information ~~currently~~set ~~expects~~forth ~~expenses~~in ~~related to~~ the ~~reduction-in-force~~press release, ~~consisting~~except ~~primarily~~for ofthe ~~cash~~information ~~severance~~set ~~and~~forth ~~termination~~under ~~benefits~~the ~~and~~headings ~~related~~“Operational ~~costs~~Restructuring,” to“Full beYear ~~approximately~~2025 ~~$7.5~~Revenue ~~million.~~Outlook” ~~These estimates are subject to a number of assumptions,~~ and ~~actual~~“About ~~results~~Standard ~~may~~BioTools ~~differ~~Inc. ~~The Company may also incur additional costs not currently contemplated due to events that may occur as a result of~~,” ortogether ~~that are associated~~ with, the ~~operational~~forward-looking ~~restructuring~~statement ~~plan~~disclaimer, ~~including~~is ~~the~~incorporated ~~reduction-in-force.~~by ~~The~~reference ~~Company~~into ~~expects~~this ~~these~~Item ~~costs~~2.02 toof bethis ~~payable~~Current ~~over~~Report ~~the~~on ~~next~~Form ~~several months~~8-K.

~~Cautionary~~Item ~~Note~~7.01. ~~Regarding~~Regulation ~~Forward-Looking~~FD ~~Statements~~Disclosure.

~~This~~The ~~Current~~information ~~Report~~set onforth ~~Form~~under ~~8-K~~the ~~contains~~headings “~~forward-looking~~Operational ~~statements~~Restructuring,” ~~within~~“Full ~~the~~Year ~~meaning~~2025 ofRevenue ~~the~~Outlook” ~~Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the expected costs~~ and ~~timing~~“About ofStandard ~~costs~~BioTools ~~associated with the reduction-in-force~~Inc.,” ~~expected~~together ~~reductions of operating expenses, and the Company’s expectations~~ with ~~respect to current revenue projections. These forward-looking statements are based on~~ the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking ~~statements~~statement ~~as a result of these risks and uncertainties~~disclaimer, ~~which~~is ~~include,~~incorporated ~~without~~by ~~limitation,~~reference ~~risks~~into ~~related~~this toItem ~~cost reduction efforts~~7.01 Inof ~~addition,~~this ~~the~~Current Company’s costs may be greater than anticipated and the workforce and operating expense reductions may have an adverse impact on the Company’s sales and development activities. Additionally, these forward-looking statements should be considered in conjunction with the cautionary statements and risk factors described in the Company’s Annual Report on Form 108-K ~~for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and its other filings filed from time to time with the Securities and Exchange Commission~~. ~~The Company does not assume any obligation to update any forward-looking statement, except as required by law.~~

~~SIGNATURE~~Item 9.01 - Financial Statements and Exhibits

~~Pursuant~~(d) ~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~Exhibits

Date:	September 17, 2025	STANDARD BIOTOOLS INC.
Exhibit No.	Description
		By:	/s/ Alex Kim
99.1	Press release issued by Standard BioTools Inc., dated November 4, 2025
		Name:	Alex Kim
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)
		Title:	Chief Financial Officer

The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Date:		November 4, 2025


	STANDARD BIOTOOLS INC.

	By:		/s/ Alex Kim
	Name:		Alex Kim
	Title:		Chief Financial Officer
			(Principal Financial and Accounting Officer)

Filing Compare · STANDARD BIOTOOLS INC.